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Summary 
The pathogenesis of Alzheimer’s disease is complex. The amyloid hypothesis has directed 
research efforts for many years, but it has recently been questioned after failed drug trials. 
Here, we review the evidence for and against and suggest that it 
might be premature to abandon the amyloid hypothesis 
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The amyloid hypothesis of Alzheimer’s disease proposes that deposition of beta-amyloid 
(Ab) protein is central to the pathogenesis of the disorder.1 It has been the foundation of 
efforts to understand the disease for almost 25 years. However, recently its validity has been 
called into question after the failure of Ab-targeting therapies in clinical trials. Some have 
even suggested that the causal link between Ab and Alzheimer’s disease has been refuted.2 
The pathology of Alzheimer’s disease 
The classical histological features of Alzheimer’s disease are a triad of Ab plaques, 
neurofibrillary tangles and neuronal cell loss.3 The first of these are insoluble extracellular 
plaques consisting of Ab, which accumulates in very high levels in the brains of those with 
Alzheimer’s disease. Ab is derived from a larger molecule, amyloid precursor protein (APP). 
APP is a trans-membrane protein, with a long extracellular N-terminal and a shorter 
intracellular C-terminal. The Ab sequence consists of some of the extracellular portion and 
part of the trans-membrane domain, and is 39–42 amino acids in length. The protein has a 
b-pleated sheet structure, and demonstrates Congo red birefringence and resistance to 
proteolysis.4 In Alzheimer’s disease, Ab is deposited in abundant extracellular plaques 
typically composed of straight fibrils, 6–10 nm in diameter. These structures are also found 
in normal ageing but in less profusion and are sometimes referred to as senile plaques. They 
are associated with dystrophic neurites and changes in microglia and astrocytes.3 Non-
fibrillar, diffuse Ab deposits, which are not associated with dystrophic neurites or reactive 
glial cells, are also found in Alzheimer’s disease and these may represent an early stage 
plaque formation. In Alzheimer’s disease these diffuse plaques are found throughout the 
central nervous system, whereas typical Ab plaques are not present in regions such as the 
spinal cord and cerebellum.4 
The second pathological structure found in Alzheimer’s disease is the neurofibrillary tangle. 
These consist of dystrophic neurites containing paired helical filaments, 10 nm in diameter. 
These paired helical filaments consist of a phosphorylated microtubule-associated protein, 
tau (MAPT).3 In the 1980s there was much debate as to which one of these is the primary 
driver of Alzheimer’s disease pathogenesis. The issue seemed to be resolved with the 
advent of a new generation of molecular genetic studies.5 
Genetics 
Early molecular genetic studies of Alzheimer’s disease focused on rare families where the 
disorder occurs exceptionally early and follows an autosomal dominant mode of inheritance. 
It was discovered that so-called familial Alzheimer’s disease is caused by mutations either in 
the APP gene itself, or in presenilin 1 and 2 (PS1 and PS2) that are involved in cleaving Ab 
from APP.5 In addition, Alzheimer’s disease frequently affects those with trisomy 21, who 
have a triplication of the APP gene.5 On these grounds, Hardy & Allsop4 postulated that 
APP mismetabolism and Ab deposition are the primary events in the disease process with 
tau phosphorylation and neurofibrillary tangle formation occurring downstream. This became 
known as the amyloid hypothesis. It later transpired that the familial Alzheimer’s disease 
genes increase levels of 42 amino acid Ab (Ab42) relative to the shorter 40 amino acid 
protein, and this form of Ab aggregates more readily into plaques.6 
Biomarkers 
The hypothesis has received further support from widely replicated biomarker studies. Brain 
Ab deposition in Alzheimer’s disease can be demonstrated in vivo using biomarkers such as 
cerebrospinal fluid (CSF) Ab42 and Ab positron emission tomography (PET) imaging.7 
Clinical diagnoses of Alzheimer’s disease and Ab pathology at autopsy correlate with low 
concentrations of CSF Ab42. Most patients with a diagnosis of Alzheimer’s have increased 
retention of radioligands for Ab on PET. Moreover, low CSF Ab and positive Ab PET show 
nearly 100% concordance.7 
Thus, a substantial body of evidence appears to support a causative, pathogenic link 
between Ab and Alzheimer’s disease. However, there are a few pieces of the Alzheimer’s 
jigsaw that do not quite fit. 
Challenges to the amyloid hypothesis 
Alzheimer’s is not an all-or-none phenomenon even at the neuro-pathological level. 
Moreover, autopsy studies find sufficient numbers of Ab plaques and neurofibrillary tangles 
to meet criteria for a diagnosis of Alzheimer’s disease in around a third of cognitively intact 
elderly people.8 This is corroborated by biomarker studies, which suggest that 20–40% of 
elderly people without cognitive impairment show significant brain Ab load, either on Ab PET 
or CSF Ab42 concentrations.8 
The topographic distribution of Ab plaques differs from neurofibrillary tangle deposition and 
neurodegenerative changes. In early Alzheimer’s disease, neural loss is predominantly in 
the hippocampus and entorhinal cortex, whereas plaques are first found in frontal regions, 
basal ganglia or elsewhere.7,9 Clinical symptoms are more closely associated with 
neurofibrillary tangles than Ab burden. However, cerebral atrophy, representing neuron and 
synapse loss, corresponds best to cognitive impairment.10 
How distant Ab plaques might induce neurofibrillary tangles or damage neurons is unclear. It 
has been proposed that soluble oligomers of Ab could be neurotoxic. Although soluble 
oligomers cannot be seen in vivo or post-mortem, they have been found to interfere with 
postsynaptic potentiation in tissue culture studies. However, the concentration of Ab 
oligomers shown to have this effect is greater than usual physiological levels.11 Another 
suggestion is that Ab plaques could act as a ‘reservoir’ eluting soluble Ab, but Ab has a 
strong tendency to polymerise and fix fragments to plaques, which makes this less likely.11 
Furthermore, many animal models based on APP and PS1 mutations have not shown 
progression to synaptic loss, neurofibrillary tangle formation and neurodegeneration.6 
Critics of the amyloid hypothesis also point out that familial Alzheimer’s disease, where the 
aetiological link with APP is strong, is rare and might be an atypical form of the disorder. 
They point to recent genome-wide association studies (GWAS), which have implicated many 
novel genes as containing risk factors for typical Alzheimer’s disease but not APP or its 
metabolising enzymes. In defence of the amyloid hypothesis, GWAS only assess common 
genetic variation and failure to find association does not exclude an important role for a 
protein in disease. Moreover, some of the genes implicated by GWAS may be involved in Ab 
processing. For example, CLU encodes clusterin, which binds soluble Ab in animal models, 
forming complexes that can cross the blood–brain barrier, and PICALM encodes 
phosphatidylinositol binding clathrin assembly protein, which has been postulated to 
increase Alzheimer’s disease risk through APP processing via endocytic pathways, resulting 
in changes in Ab levels.12 
Clinical trials 
The biggest challenge to the amyloid hypothesis has come from the failure of phase III trials 
of anti-Ab therapies2 despite promising results in animal models.6 Critics point to notable 
therapeutic failures, such as semagacestat, an inhibitor of gamma (g)-secretase, an enzyme 
responsible for the cleavage of APP to produce pathogenic Ab.13 Participants in the active 
treatment arm had poorer cognitive out-comes, and the trial was terminated. The trial of 
immunisation with aggregated human Ab, AN1792, was halted when some participants 
developed autoimmune encephalopathy, and there was no effect on disease progression.14 
This raises a key question. Does the failure of these trials effectively refute the amyloid 
hypothesis? There are two general reasons why this conclusion might be premature. First, 
there could have been insufficient target engagement. Second, the drugs may have been 
administered too late in the disease process. 
In an analysis of six programmes testing anti-Ab therapies, Karran & Hardy15 identified 
various deficiencies. This suggested that the failure of phase III trials of anti-Ab agents might 
be because of problems with pharmacokinetics, dosing, outcome measures etc., rather than 
shortcomings of the amyloid hypothesis.15 An analysis by pharmaceutical industry 
investigators16 reached a similar verdict: negative trials did not demonstrate sufficient target 
engagement to assess whether reducing Ab load could modify the course of Alzheimer’s 
disease. 
Early research assumed that abnormal deposition of Ab is a proximal cause of 
neurodegeneration in Alzheimer’s disease. An alternative model is that production of Ab at 
abnormal levels begins much earlier in life, is integral to the inception of the disease 
process, but the subsequent pathological cascade becomes autonomous. If this were true, 
anti-Ab therapies would only be effective if administered early in the disease process. 
Support for this view comes from biomarker studies showing a clear sequence of 
abnormalities as the disease progresses.10 The earliest markers of brain Ab deposition are 
reductions in CSF Ab42 followed by increased Ab PET tracer uptake. These changes occur 
in the ‘preclinical’ phase17 and, by the time cognitive impairment is clinically detected, Ab 
markers have plateaued. Subsequently, neuronal injury and neurodegeneration 
predominate. These are shown by increased CSF tau and cerebral atrophy on structural 
magnetic resonance imaging. Decreased fluorodeoxyglucose uptake on PET indicates 
accompanying synaptic dysfunction. These markers, which become abnormal later in the 
disease, correlate closely with clinical symptoms7 (Fig. 1). 
The failed therapeutic trials may also support this chronological pattern. For example, the 
AN1792 immunisation,14 which did not improve cognition and had minimal effect on neural 
loss, gliosis and tau accumulation, did reverse Ab deposition. The number of patients 
followed up, however, was small. This is consistent with the view that, in its later stages, the 
pathogenic process is not dependent on Ab deposition, even if it is triggered by it. This 
means that the timing of any intervention in the Alzheimer’s pathological process is crucial. It 
also makes Ab levels an equivocal proxy end-point for clinical trials at least in the later 
stages of the process.18 
Among the strongest recent evidence that reducing Ab cleavage may protect against 
Alzheimer’s disease is the discovery of a rare mutation in the APP gene that is associated 
with decreased Ab synthesis and which protects against Alzheimer’s disease and cognitive 
decline in elderly people.19 Further support for the amyloid hypothesis has come from 
recent work using human neural stem-cell-derived cultures in a three-dimensional system to 
model the effects of familial Alzheimer’s disease mutations. They deposited Ab and 
aggregates of phosphorylated tau. Further-more, inhibition of Ab generation with b-or g-
secretase inhibitors decreased both Ab and tau.19 
 
Fig. 1 Biomarkers of the Alzheimer’s pathological cascade 
Beta-amyloid (Ab) is indicated by low cerebrospinal fluid (CSF) Ab42 or positron emission 
tomography (PET) Ab imaging. Tau neuronal injury and dysfunction is shown by CSF tau or 
fluorodeoxyglucose-PET. Cerebral atrophy is measured with structural magnetic resonance 
imaging. MCI, mild cognitive impairment. Reprinted with permission from Elsevier Limited. 
Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical 
model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010; 
9: 119–28. 
Implications 
The emerging evidence suggests that Ab deposition occurs early in Alzheimer’s disease, 
and the correct timing of interventions may turn out to be crucial. Identifying asymptomatic 
individuals who have Ab-related neurodegeneration will be important, as not all patients 
currently selected for Alzheimer’s disease drug trials have Ab-positive PET imaging.20 Trials 
of anti-Ab therapy in cognitively normal elderly people with positive Ab biomarkers and 
younger, asymptomatic, individuals who carry a familial Alzheimer’s disease mutation are 
underway21,22 and, if successful, will support the need for anti-Ab therapies to be given 
before cognitive decline has become established. 
There is increasing interest in the possibility that the key to treating the disorder may be to 
identify those at risk long before they develop symptoms, as hyperlipidaemia and 
hypertension are treated years before myocardial or cerebral infarction. This will require the 
right anti-Ab drugs to be given to the right patients, those at high risk and at the right time, 
before irreversible changes have taken place.10 This will require much further research. 
Although biomarkers can detect asymptomatic amyloidosis, large longitudinal studies will be 
needed to investigate their usefulness as predictive tests.11 
Geneticprofilingmayalsohavearole,usingrisk profile scores based on panels of single 
nucleotide polymorphisms that are associated with increased risk.12 
Despite two decades of intensive work, the amyloid hypothesis has not led to the hoped for 
therapeutic advances. This has caused some to question its validity and to ask whether 
efforts aimed at reducing Ab synthesis are ever likely to be successful. The finding of a 
mutation in APP that protects against Alzheimer’s disease and reduces the production of Ab 
suggests that it may be premature to write off the amyloid hypothesis. Moreover, the 
negative results of therapeutic trials should be interpreted in the light of evidence that Ab 
deposition occurs early in the preclinical phase of the illness. The emerging paradigm of 
targeting treatments at asymptomatic high-risk individuals remains untested, but if this gains 
support, it will signal a sea change in the way in which Alzheimer’s disease is treated with a 
move from tertiary to secondary prevention. 
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